xanamem
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 23, 2017 (NCT02727699)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 2
- Central Nervous System · Phase 1
- Cerebrospinal Fluid · Phase 1
- Cognition · Phase 1
- Cognitive Dysfunction · Phase 2
- Dementia · Phase 2
- Depressive Disorder · Phase 2
- Electrocardiography · Phase 1
- Healthy Aging · Phase 1
- Hydrocortisone · Phase 1
- Major Depressive Disorder · Phase 2
- Peripheral Nervous System Diseases · Phase 1
- Safety · Phase 1
- Small Fiber Neuropathy · Phase 1
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- xanamem
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06125951 | Phase 2 | Dec 31, 2023 | Actinogen Medical |
| NCT05657691 | Phase 2 | Nov 28, 2022 | Actinogen Medical, Axiom Clinical Research of Florida |
| NCT03830762 | Phase 1 | Jan 21, 2019 | Actinogen Medical, ICON |
| NCT02727699 | Phase 2 | Mar 23, 2017 | Actinogen Medical, ICON |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Actinogen Medical | For profit | 4 | 4 | 2 | 2017 |
| ICON | For profit | 2 | 0 | 2 | 2017 |
| Axiom Clinical Research of Florida | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1